Vogenx, Inc. (VOGX)
| Market Cap | 240.06M+24.3% |
| Revenue (ttm) | n/a |
| Net Income | -1.65M |
| EPS | -0.22 |
| Shares Out | 14.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 237,864 |
| Open | 16.80 |
| Previous Close | 16.39 |
| Day's Range | 14.79 - 16.80 |
| 52-Week Range | 12.95 - 38.41 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 55.00(+240.35%) |
| Earnings Date | n/a |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VOGX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
$VOGX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VOGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VOGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VOGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VOGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VOGX from public contracts
Source: USAspending.gov
VOGX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VOGX’s recent data — informational, not investment advice